Twist Bioscience (NASDAQ:TWST) Insider Sells $128,494.60 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 949 shares of Twist Bioscience stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $128,494.60. Following the completion of the transaction, the insider owned 62,840 shares of the company’s stock, valued at $8,508,536. The trade was a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Friday, October 2nd, Dennis Cho sold 9,514 shares of Twist Bioscience stock. The shares were sold at an average price of $188.88, for a total transaction of $1,797,004.32.
• On Monday, September 21st, Dennis Cho sold 348 shares of Twist Bioscience stock. The shares were sold at an average price of $165.49, for a total transaction of $57,590.52.
• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The stock was sold at an average price of $122.62, for a total transaction of $50,519.44.

Twist Bioscience Stock Up 0.1%

TWST opened at $120.79 on Friday. The company has a 50 day moving average of $151.35 and a 200 day moving average of $91.08. The company has a market cap of $7.57 billion, a PE ratio of -54.41 and a beta of 2.25. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. TD Cowen increased their target price on Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. BWS Financial reiterated a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. Canaccord Genuity Group boosted their price objective on Twist Bioscience from $120.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Robert W. Baird boosted their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, Guggenheim increased their price objective on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $153.00.

Key Headlines Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of TWST. Western Wealth Management LLC bought a new stake in Twist Bioscience during the 1st quarter worth approximately $31,000. Strs Ohio purchased a new stake in Twist Bioscience in the 1st quarter worth approximately $33,000. Root Financial Partners LLC bought a new position in Twist Bioscience in the 3rd quarter valued at $33,000. PNC Financial Services Group Inc. boosted its holdings in Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the period. Finally, Fifth Third Bancorp bought a new position in Twist Bioscience in the 1st quarter valued at $54,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.